<DOC>
	<DOCNO>NCT01643824</DOCNO>
	<brief_summary>This phase II study evaluate effectiveness hypofractionated proton beam therapy ( PBT ) HCC patient hepatitis B endemic area .</brief_summary>
	<brief_title>Hypofractionated Proton Beam Radiotherapy Hepatocellular Carcinoma</brief_title>
	<detailed_description>The primary endpoint local progression free survival . The trial single arm phase II trial historical arm . The expected 3-year local progression free survival patient HCC patient treat proton beam therapy would 80 % . With power 80 % type I error level 10 % , evaluable 40 patient require reject null hypothesis true 3-year local progression free survival rate ≤65 % . Considering 10 % unevaluable patient due loss follow , total 45 eligible patient arm enrol .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>HCC diagnose ( ) presence risk factor include hepatitis B C virus liver cirrhosis , serum afetoprotein ( AFP ) level great 200 IU/ml radiologically compatible feature HCC one CT/MRI/angiograms , ( ii ) presence risk factor include hepatitis B C virus liver cirrhosis , serum afetoprotein ( AFP ) level le 200 IU/ml , radiologically compatible feature HCC two CT/MRI/angiograms ( iii ) histological confirmation HCC patient prospective suitable refuse treatment , surgery local ablation therapy , recurrent residual tumor treatment . without evidence extrahepatic metastasis All target tumor must encompassable within single irradiation field ( 15x15 cm maximum ) previous treatment target tumor form RT liver function ChildPugh class A B7 ( ChildPugh score ≤7 ) Age ≥18 year performance status 0 2 Eastern Cooperative Oncology Group ( ECOG ) score WBC count ≥ 2,000/mm3 ; hemoglobin level ≥ 7.5 g/dL ; platelet count ≥ 25,000/mm3 ; adequate hepatic function ( total bilirubin ≤ 3.0 mg/dL ; AST ALT &lt; 5.0× upper limit normal ; ascites ) serious comorbidities liver cirrhosis write informed consent evidence extrahepatic metastasis age &lt; 18 year liver function ChildPugh class B89 C ( ChildPugh score &gt; 7 ) previous history form RT adjacent target tumor poor performance status 3 4 Eastern Cooperative Oncology Group ( ECOG ) score multicentric HCCs , except follow two condition : *multinodular aggregate HCC could encompass single clinical target volume within single irradiation field ( 15x15 cm maximum ) *lesions target tumor judge control prior surgery and/or local ablation therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>